3DBio Therapeutics is a biologics and bioprinting company with a focus on regenerative medicine that precision manufactures living tissues to allow replacement of each individual patient’s parts with tissues designed and created specifically for them. The company’s purpose is to deliver living tissue to patients to treat disease and congenital medical conditions. They develop novel 3D-bioprinting and materials technologies, and focus on clinical applications with high unmet need—in particular, tissues with limited regenerative capacity whose function depends on complex 3D geometry.
3DBio’s technology includes a comprehensive suite to enable therapeutic-grade manufacturing of living tissues—from a GMP-compatible 3D-bioprinter, to their novel cell processes. These platforms enable the creating of de novo patient-specific living tissue and body parts. The primary focus areas are initially craniofacial and spine, with a wide applicability to provide tissues with therapeutic benefit throughout the body.
3D Bio Therapeutics was cofounded by a professor in the Cornell University College of Engineering. The company’s foundational technology is licensed from Cornell University.